Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-23
2011-08-23
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C530S300000, C530S326000, C530S328000
Reexamination Certificate
active
08003609
ABSTRACT:
The present invention provides a method for ameliorating inflammatory and/or neuropathic pain in a subject by modifying the activity of N-methyl-D-aspartate (NMDA) receptors in cells of the subject by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex.
REFERENCES:
patent: 4994446 (1991-02-01), Sokolovsky
patent: 5523323 (1996-06-01), Maccecchini
patent: 5888996 (1999-03-01), Farb
patent: 5914403 (1999-06-01), Nichols
patent: 6649605 (2003-11-01), Olesen et al.
patent: 6653354 (2003-11-01), Franks
patent: 6703489 (2004-03-01), Ish-Horowicz et al.
patent: 2002/0077322 (2002-06-01), Ayoub
patent: 2002/0123510 (2002-09-01), Chenard
patent: 2003/0050243 (2003-03-01), Tymlanski
patent: 2003/0022499 (2003-12-01), Land et al.
patent: 2004/0082543 (2004-04-01), Cheung
patent: 2005/0222042 (2005-10-01), Salter et al.
patent: 1244638 (2002-10-01), None
patent: WO 97/46877 (1997-12-01), None
patent: WO 2005/012551 (2005-02-01), None
patent: WO 2005/059993 (2005-10-01), None
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495.
Planellis-Cases, R. et al. Small Molecules Targeting the NMDA Receptor Complex at Drugs for Neuropathic Pain, Mini Review Med Chem., Nov. 2003, vol. 3, No. 7, pp. 749-756.
M. Aarts et al, “Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions”, Science, 298:846-850 (Oct. 2002).
D. Ali et al, “NMDA receptor regulation by Src kinase signaling in excitatory synaptic transmission and plasticity”, Current Opinion in Neurobiology, 11:336-342 (2001).
M. Brown et al, “Regulation, substrates and functions of src”, Biochimica et Biophysica Acta, 1287:121-149 (1996).
M. Chen et al, “Tyrosine kinase and tyrosine phosphatase participate in regulation of interactions of NMDA receptor submit 2A with Src and Fyn mediated by PSD-95 after transient brain ischemia”, Neuroscience Letters, 339:29-32 (Mar. 20, 2003).
J. Coyle et al, “Oxidative stress, glutamate, and neurodegenerative disorders”, Science, 262:689-695 (Oct. 1993).
S. Davis et al, “Selfotel in acute ischemic stroke possible neurotoxic effects of an NMDA antagonist”, Stroke, 31:347-354 (Feb. 2000).
V. Dawson et al, “Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures”, Proc. Natl. Acad. Sci. USA, 88:6368-6371 (Jul. 1991).
R. Dingledine et al, “The glutamate receptor ion channels”, Pharmacological Reviews, 51(1):7-61 (1999).
I. Fearnley et al, “Conservation of sequences of subunits of mitochondrial complex I and their relationships with other proteins”, Biochimica et Biophysica Acta, 1140:105-134 (1992).
A. Fix et al, “Neuronal vacuolization and necrosis Induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex”, Experimental Neurology, 123:204-215 (1993).
D. Friel et al, “Mitochondria as regulators of stimulus-evoked calcium signals in neurons”, Cell Calcium, 28(5/6):307-316 (2000).
Gingrich et al., (2001) Society for Neuroscience Abstract. Program #33.14, poster location C-65. Abstract, p. 1 of 1.
Gingrich et al., “Unique domain anchoring of SRC to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2”, PNAS, 101(16): 6237-6242 (2004).
Gingrich et al., “Correction for Gingrich et al, PNAS, 101(16) 6237-6242 (2004)”, PNAS, 103(25): 9744 (2006).
A. Gorman et al, “Role of Mitochondria in Neuronal Apoptosis”, Developmental Neuroscience, 22:348-358 (2000).
W. Guo et al, “Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia”, The Journal of Neuroscience, 22(14):6208-6217 (Jul. 2002).
J. Gyuris et al, “Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2”, Cell, 75:791-803 (Nov. 1993).
J. Henderson et al, “The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function”, Neuron, 32:1041-1056 (Dec. 2001).
S. Hirsch et al, “A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction”, Pharmacology Biochemistry and Behavior, 56(4):797-802 (1997).
Y-Q. Huang et al,.“CAKB/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus”, Neuron, 29:485-496 (Feb. 2001).
N. Ibrahim et al, “Regulation of mitochondrial protein synthesis at the polyribosomal level”, The Journal of Biological Chemistry, 251(1):108-115 (Jan. 1976).
C. Ikonomidou et al, “Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?”, The Lancet Neurology, 1:383-386 (Oct. 2002).
M. Ingman et al, “NADH dehydrogenase subunit 2 [Homo sapiens]”, Genebank, Accession No. AAK17260 (Aug. 22, 2003).
E. Kandel, “The molecular biology of memory storage: a dialogue between genes and synapses”, Science, 294:1030-1038 (Nov. 2001).
M. Kennedy et al, “Biochemical and immunochemical evidence that the ‘major postsynaptic density protein’ is a subunit of a calmodulin-dependent protein kinase”, Proc. Natl. Acad. Sci. USA, 80(23):7357-7361 (Dec. 1983).
E. Kramar et al, “Integrins modulate fast excitatory transmission at hippocampal synapses”, The Journal of Biological Chemistry, 278(12):10722-10730 (Mar. 2003).
S. Lei et al, “Platelet-derived growth factor receptor-Induced feed-forward Inhibition of excitatory transmission between hippocampal pyramidal neurons”, J. Biol. Chem., 274(43):30617-30623 (Oct. 1999).
B. Lin et al, “Integrins regulate NMDA receptor-mediated synaptic currents”, J. Neurophysiol., 89:2874-2878 (May 2003).
X. Liu et al, “Potentiation of formalin-evoked adenosine release by an adenosine kinase inhibitor and an adenosine deaminase inhibitor in the rat hind paw: a microdialysis study”, European Journal of Pharmacology, 408:143-152 (2000).
X. Liu et al, “Regulation of c-Src tyrosine kinase activity by the Src SH2 Domain”, Oncogene, 8:1119-1126 (1993).
W-Y. Lu et al, “G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors”, Nature Neuroscience, 2(4):331-338 (Apr. 1999).
Y. Lu et al, “Src activation in the induction of long-term potentiation in CA1 hippocampal neurons”, Science, 279:1363-1367 (Feb. 1998).
L. Luttrell et al, “The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals”, Journal of Cell Science, 115:455-465 (2002).
J. MacDonald et al, “Regulation of N-methyl-D-aspartate receptors revealed by intracellular dialysis of murine neurones in culture”, Journal of Physiology, 414:17-34 (1989).
R. Malenka et al, “Long-term potentiation—a decade of progress?”, Science, 285:1870-1874 (Sep. 1999).
P. Mariottini et al, “Identification of the polypeptides encoded in the unassigned reading frames 2, 4, 4L, and 5 of human mitochondrial DNA”, Proc. Natl. Acad. Sci. USA, 83:1563-1567 (Mar. 1986).
M. Marusich et al, “Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fibroblasts:a comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome”, Biochimica et Biophysics Acta, 1362:145-159 (1997).
G. Morris et al, “Failure of the competitive N-methyl-D-aspartate antagonist Selfot
Gingrich Jeffrey R.
Salter Michael W.
Alston and Bird LLP
Lockard Jon M
Saoud Christine J
The Hospital for Sick Children
LandOfFree
Method for ameliorating pain by modification of NMDA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for ameliorating pain by modification of NMDA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for ameliorating pain by modification of NMDA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666495